Tiziana Life Sciences
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 9
- Market Cap
- $125.8M
- Introduction
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Drug: ForalumabOther: Placebo
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 54
- Registration Number
- NCT06292923
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Milciclib in Combination With Gemcitabine in Advanced NSCLC
- Conditions
- NSCLC
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 28
- Registration Number
- NCT05651269
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05028946
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
- Conditions
- Primary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisMultiple Sclerosis
- Interventions
- Drug: Intranasal Foralumab SolutionDrug: Placebo
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT05029609
In-patient COVID-19 Study of Intranasal Foralumab
- Conditions
- COVID-19 Lower Respiratory InfectionCovid19COVID-19 Respiratory Infection
- Interventions
- Drug: ForalumabOther: Placebo
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT04983446
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
- Conditions
- NAFLDNASH - Nonalcoholic SteatohepatitisT2DM (Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Tiziana Life Sciences LTD
- Registration Number
- NCT03291249
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 31
- Registration Number
- NCT03109886
- Locations
- 🇮🇹
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
🇬🇷Ippokrateio General Hospital of Athens, Athens, Greece
🇮🇹Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 30
- Registration Number
- NCT01301391
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, (mi), Italy
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸NIH, Center for Cancer Research, Medical Oncology, Bethesda, Maryland, United States
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 72
- Registration Number
- NCT01011439
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, (mi), Italy
🇮🇹Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy
🇫🇷Hopital Larrey, Toulouse Cedex, France